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ABSTRACT
Objectives Healthcare workers have greater exposure 
to SARS-CoV-2 and an estimated 2.5- fold increased risk 
of contracting COVID-19 than the general population. 
We wished to explore the predictive role of basic 
demographics to establish a simple tool that could help 
risk stratify healthcare workers.
Setting We undertook a review of the published literature 
(including multiple search strategies in MEDLINE with 
PubMed interface) and critically assessed early reports on 
preprint servers. We explored the relative risk of mortality 
from readily available demographics to identify the 
population at the highest risk.
Results The published studies specifically assessing 
the risk of healthcare workers had limited demographics 
available; therefore, we explored the general population in 
the literature. Clinician demographics: Mortality increased 
with increasing age from 50 years onwards. Male sex at 
birth, and people of black and minority ethnicity groups 
had higher susceptibility to both hospitalisation and 
mortality. Comorbid disease. Vascular disease, renal 
disease, diabetes and chronic pulmonary disease further 
increased risk. Risk stratification tool: A risk stratification 
tool was compiled using a white female <50 years with 
no comorbidities as a reference. A point allocated to risk 
factors was associated with an approximate doubling in 
risk. This tool provides numerical support for healthcare 
workers when determining which team members should 
be allocated to patient facing clinical duties compared with 
remote supportive roles.
Conclusions We generated a tool that provides a 
framework for objective risk stratification of doctors and 
healthcare professionals during the COVID-19 pandemic, 
without requiring disclosure of information that an 
individual may not wish to share with their direct line 
manager during the risk assessment process. This tool 
has been made freely available through the British Medical 
Association website and is widely used in the National 
Health Service and other external organisations.
The Health and Safety Executive mandates 
that all employers protect their employees 
from harm under the Management of Health 
and Safety at Work Regulations 1999. There 
are three key elements to this: identify what 
could cause the injury (the hazard), decide 
how likely that someone could be harmed 
and how seriously they are likely to be 
harmed (the vulnerability) and what actions 
can be taken to minimise this risk (the mitiga-
tion). In the current coronavirus pandemic, 
it is clear that COVID-19 is the agent that 
causes injury. The risk of harm is higher in 
Strengths and limitations of this study
 ► There is an increased risk of mortality in the clinical 
workforce due to effects of COVID-19.
 ► This article outlines a simple risk stratification tool 
that helps to quantify an individual’s biological risk.
 ► This tool does not incorporate other external factors, 
such as high- risk household members or those at 
higher risk of mental health issues, that may require 
additional consideration when allocating clinical du-
ties in an appropriate clinical domain.
 ► This population- based analysis did not explain the 
reason for the very high risk observed in black, 
Asian and minority ethnic healthcare workers, sug-
gesting there are other issues at play that require 
addressing.
 ► The risk assessment tool presented continues to 
be tested and validated against primary care da-
tabases—the most up- to date version will remain 
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healthcare workers compared with the general popula-
tion,1 and thus action is required to minimise this risk. In 
the early phase of the pandemic, the Office of National 
Statistics reported medical practitioners had a 2.5- fold 
increase (95% CI, 1.5 to 4.3) in mortality compared with 
the average mortality from 2014 to 2018.2 This compared 
with a 50% increased risk in the age- matched general 
population (HR, 1.5; 95% CI, 1.5 to 1.6). This trend was 
in keeping with observations in other countries of higher 
mortality among healthcare workers.3–7
While reasonable measures must be taken to protect all 
staff members from infection, individuals thought to be 
particularly vulnerable to infection may require modifica-
tion of their practice. The Faculty of Occupational Medi-
cine and National Health Service (NHS) Employers in 
England produced recommendations that all healthcare 
practitioners should receive an occupational risk assess-
ment.8 9 These frameworks were borne of the observation 
that certain ethnic groups appeared to be at higher risk 
than others9 while recognising there are several other 
biological parameters, such as age, male sex, prior cardio-
vascular disease and diabetes, that were also associated 
with adverse outcomes. These predictors of hospital-
isation, progression to intensive care units (ICUs) and 
ultimately death were reaffirmed in the Public Health 
England document.10
Despite the intention to improve risk assessment in 
healthcare settings, these frameworks failed to produce an 
objective tool to improve stratification across the health-
care system. The need for such a tool is highlighted by 
the disproportionate impact of COVID-19 on healthcare 
workers of black, Asian and minority ethnicity (BAME) 
descent. Up to 21 April 2020, 36% and 27% of the fatali-
ties came from people of Indian Asian heritage and black 
African descent, respectively, despite those populations 
only representing 10% and 6% of the workforce. Existing 
data suggest that biological parameters do not account 
for all the increased risk, raising the possibility of cultural 
differences in self- assessment of risk or systemic chal-
lenges in modification of hazards for people of different 
ethnic background. Indeed, these cultural challenges 
have been proposed as a contributor to the increased risk 
in BAME populations.
Using published data on the demographics of those 
who have been hospitalised, and ultimately died, due to 
COVID-19 compared with the general population prev-
alence in these determinants, we have developed an 
objective risk stratification (ORS) tool. Creation of such 
an objective tool that can be applied equally and without 
favour to all healthcare practitioners allows biological risk 
to be evaluated and is used to reduce hazard.
METHODS
We reviewed the published literature (including multiple 
search strategies in MEDLINE with PubMed interface) 
and EMBASE and critically assessed early reports on 
medRxiv, a preprint server (https://www. medrxiv. org/) 
(date of last search: 21 April 2020).
Eligibility criteria
Studies were included according to the following criteria.
Search terms
COVID-19, Coronavirus, SARS- CoV2, Coronavirus AND 
mortality, hospitalisation.
Participants
As it had already been observed that there were differ-
ences in the impact of COVID-19 in different geographic 
locations and different socioeconomic circumstances, we 
limited the search to reports from the UK.
Outcomes
Given there are selection biases in testing for corona-
virus, COVID-19 care and reporting, we predominantly 
explored the ‘hard outcomes’ of admission to the ICU 
and mortality. Although the occurrence of mild symptoms 
and asymptomatic disease may have an impact on the 
ability of health systems to function and on nosocomial 
spread, it would not cause significant long- term conse-
quences and thus was not considered as an outcome.
Ethics statement
This project was based on secondary analysis of existing 
data; therefore, ethics approval was not required.
Information sources and search strategy
We searched the following electronic databases: 
MEDLINE, EMBASE and the preprint server medRxiv 
from inception to 22 April 2021. Only English- language 
articles were included. The reference lists of included 
reports were also searched for additional reports. The 
majority of the existing analyses are based on retro-
spective and often single- centre series. No published or 
completed prospective cohort studies or randomised 
controlled trials were present in this literature search. We 
reviewed the case reports and cohort studies and, where 
possible, the local demographics. Because of the urgency 
to improve risk stratification in the middle of the ongoing 
pandemic, reports were considered that otherwise would 
not have met the rigours of a systematic review. All reports 
were assessed for risk of bias (ROB) using the Cochrane 
ROB V.2.0 tool11; however, this assessment was used to 
inform the weighting given to the information contained 
there when being reviewed by the experts to form a 
consensus risk assessment tool.
The nature of the risk tool was the subject of several 
focus group meetings. The requirement was for it to be 
simple to complete, be objective such that it could stratify 
the vulnerability of exposure and not reveal personal 
information because it may be misused by ‘line managers’ 
after the pandemic. The latter requirement was a partic-
ular request from the BAME representatives to the focus 
groups, who feel that they are particularly vulnerable to 
workplace bullying.12 This results in the requirement for a 
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single- page risk assessment tool that presents cumulative 
factors that could be completed ahead of a conversation 
with the designated manager and a clear stratification of 
vulnerability.
Risk of hospitalisation and mortality was analysed 
compared with population prevalence. Multivariate Cox 
regression modelling was used to estimate adjusted HR. 
Risk was normalised to a female aged 40–49 years, and 
an integer to approximate the impact of demographics, 
such as age,13 ethnicity14 and important comorbidities,15 
was assigned.
There are two principal sources of data: the Intensive 
Care National Audit and Research Centre (ICNARC) 
report that collated data from the national clinical 
audit covering all NHS adult, general intensive care 
and combined intensive care/high dependency units in 
England, Wales and Northern Ireland, plus some addi-
tional specialist and non- NHS critical care units, and 
the OpenSafely report that quantified a range of risk 
factors for death from COVID-19 based on primary care 
records.16 Given these two principal sources of data, we 
collated and compared the risk of admission to intensive 
therapy unit (ITU) and mortality from the ICNARC study 
with the general population data.17 Predictive risk model-
ling was used to predict the vulnerability of individuals.
This risk tool was standardised to the risk of mortality 
of a female under the age of 50 years. A point was then 
allocated for each approximate doubling in risk. Given 
the likely colinearity of multiple risk factors where risk 
was a greater multiple than 2, it was rounded down. As 
the purpose of this objective risk assessment tool is to 
supplement rather than supplant existing Public Health 
England recommendations, characteristics that warranted 
shielding according to the NHS Digital shielded patient 
list algorithm were discounted. Risk factors were only 
included in the derived objective risk assessment tool if 
they CI of their independent predictive role did not cross 
the line of unity (ie, p<0.05). Receiver operating charac-
teristic curves were used to identify the scores that would 
best identify high risk (risk of admission to ITU or death) 
or moderate risk (risk of hospitalisation but no long- term 
complications).
Once a simplified risk tool was compiled, it was vali-
dated using the composite HRs derived from the Open-
Safely platform report.18 We evaluated the risk in 317 cases 
within a trust and stratified them into low, middle and 
high risk. Agreement between the objective risk assess-
ment tool and the calculated HR was evaluated using 
Cohen’s kappa coefficient for inter- rater agreement.
RESULTS
Multiple global observational studies were identified 
describing the risk of hospitalisation and mortality due 
to COVID-19; however, there was significant heteroge-
neity in these studies, such that the robust nature of the 
data when applying to a UK population of healthcare 
providers was questionable (online supplemental table 
1). One point of agreement, however, was that multiple 
comorbidities appeared to confer cumulative risk. As a 
result, the development of a risk calculator was based 




In all age groups, mortality was at least twice as high in 
men compared with women (table 1). Compared with 
those under the age of 50 years, in men mortality doubled 
in the age group of 50–59 years, quadrupled in the age 
group of 60–69 years and was 12 times higher in those 
aged above 70 years.
Ethnicity
People of non- white ethnic origin were at a higher risk of 
hospitalisation and mortality than the general population. 
Raw data suggested there was a 2- fold to 4- fold increased 
risk compared with the local population for COVID-19 
compared with non- COVID-19 viral pneumonia over the 
previous 3 years .19 This was, in part, explained by the 
premature onset of comorbidities that also conferred 
risk, such as type 2 diabetes, ischaemic heart disease 
and stroke.20–23 After multivariate adjustment, however, 
some of this risk could not be accounted for with conven-
tional risk factors, and therefore an ethnicity adjustment 
was included. This is most accentuated in people of 
black African descent where the risk was 2- fold elevated 
compared with those of white European descent. People 
of Indian Asian descent also had an approximately 50% 
Table 1 Clinical demographics
Age group Mortality
  <50 years 1 (reference)
  50–69 years 4.02 (95% CI, 2.88 to 5.63)
  70–79 years 9.59 (95% CI, 6.89 to 13.3)
  ≥80 years 13.59 (95% CI, 9.79 to 18.85)
Sex at birth
Proportion of admissions
  Male 60.2%
  Female 39.8%
Mortality once admitted
  Male 1.2 (95% CI, 1.11 to 1.29)
  Female 1 (reference)
Composite risk
  Male 1.96
  Female 1 (reference)
Mortality by age group and risk of admission and subsequent 
mortality stratified by sex at birth (features of 16 749 hospitalised 
UK patients with COVID-19 using the ISARIC WHO Clinical 
Characterisation Protocol).18
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increased risk of hospitalisation compared with their 
European counterparts.
Socioeconomic status
For influenza, 25% of ICU admissions are people from 
the most deprived quintile compared with just 15% from 
the least deprived (online supplemental table 2). Once 
on ITU, however, there were only slight differences in 
mortality between people in the most deprived and least 
deprived status.
Comorbidities
There are multiple comorbid factors that are each incre-
mentally associated with increased mortality. The most 
common recorded comorbidities are chronic cardiac 
disease (29%), uncomplicated diabetes (19%), chronic 
pulmonary disease excluding asthma (19%) and asthma 
(14%) (online supplemental table 2).24 These repre-
sented 16 749 patients: 7924 (47%) patients had no docu-
mented reported comorbidity. Although numerically not 
a large percentage of patients, those with active malig-
nant neoplasms, chronic kidney disease or liver disease 
were between 3- fold and 5- fold increased risk of hospi-
talisation, respectively, compared with the prevalence 
in the general population. Although data were sparse, 
there was a suggestion that other conditions requiring 
long- term immunosuppressant therapy was similarly over- 
represented by approximately 50% (data not shown). 
Similarly, dementia was associated with a significantly 
higher risk of both hospitalisation (~7.7 times increase) 
and mortality in hospital (39% increase) than the general 
population. There has been limited relevance for modi-
fying clinical exposure, although it may be pertinent 
if using this tool to assess risk within the community. 
Contrary to many popular media reports, the increased 
risk of hospitalisation and mortality for people living with 
obesity was, in the first stages, accounted for by comorbid-
ities such as diabetes, ischaemic heart disease and stroke. 
Beyond a body mass index of 35 kg/m2 (or 30 kg/m2 in 
people of Asian and black African descent), however, 
there was an independent predictive increased risk.
Generating an ORS tool
By considering each of the demonstrated associated 
factors for COVID-19 hospitalisation and subsequent 
mortality, a risk stratification tool was generated, which 
may be considered when allocating clinical individuals to 
standard or higher risk duties (table 2). The risk model 
attributes a point for every approximate doubling of risk 
compared with the reference population (HR ≥1.75 and 
≤2.25). By adding the risk score from each category, it 
gives every individual a personal risk score that provides 
an estimate of their biological hazard. A high risk score 
was defined
When validating this tool against the 317 predefined 
cases in a single NHS trust, the outcomes of the ORS tool 
correlated well with absolute risk scores in the OpenSafely 
platform (Cohen’s kappa, 0.76; SD, 0.071; p<0.0001; 
table 3). A final validation was performed against the 
Public Health England document ‘Disparities in the risk 
and outcomes of COVID-19’.10 This demonstrated a simi-
larly high level of agreement (Cohen’s kappa, 0.81; SD, 
0.063; p<0.0001).
Pregnancy
There are currently insufficient data to make any mean-
ingful assessment about the risk of COVID-19 to either 
the mother or the unborn child. Early reports from 
Table 2 Suggested objective risk stratification tool for 
individuals not already identified as ‘vulnerable’ by the NHS 
Digital shielded patient list
Risk factor Indicator Adjustment
Age >50 1
  >60 2
  >70 4
  >80 6
Sex at birth Female 0
  Male 1
Ethnicity White European 0
  Black African descent 2
  Indian Asian descent 1
  Filipino descent 1
  Other (including Mixed race) 1
Diabetes and obesity (Type 1 or type 2) 
uncomplicated*
1
  (Type 1 or type 2) complicated* 2
  BMI ≥35 kg/m2 (>30 kg/m2 if of 
BAME descent)
1
Cardiovascular disease Angina, previous MI, stroke or 
cardiac intervention
1
  Heart failure 2
Pulmonary disease Asthma 1
  Non- asthma chronic 
pulmonary disease
1
  Either of the above requiring 
oral corticosteroids in the 
previous year
1
Malignant neoplasm Active malignancy 3
  Malignancy in remission 1
CKD CKD 3 or 4









  Low risk <3
  Medium risk 3–5
  High risk ≥6
*Complicated diabetes=presence of microvascular complications or HbA1c 
≥64 mmol/mol.
BAME, black, Asian and minority ethnicity; BMI, body mass index; CKD, 
chronic kidney disease; MI, myocardial infarction; NHS, National Health 
Service; NHS, National Health Service.
 on N
ovem









pen: first published as 10.1136/bm






5Strain WD, et al. BMJ Open 2021;11:e042225. doi:10.1136/bmjopen-2020-042225
Open access
the UK and the USA suggest there is no risk to either; 
however these are based on small numbers.25 26 Given 
the unknown risk to both parties, although pregnancy is 
not considered as a risk factor in its own right, we would 
recommend all people who are pregnant be regarded as 
high risk and offered the option to shield.
DISCUSSION
There are currently no reliable data for COVID-19- 
related deaths in healthcare professionals, including 
doctors, and surprisingly few data on the differences in 
risk in different healthcare settings. There is an urgent 
need for high- quality research. We have applied general 
population risk factors to healthcare workers to generate 
a simplified biological risk stratification tool and made 
this freely available on the British Medical Association’s 
website at https://www. bma. org. uk/ media/ 3820/ bma- 
covid- 19- risk- assessment- tool- february- 2021. pdf. This may 
serve to inform employers when allocating specific duties 
within the healthcare provision system to fulfil their duty 
of care to their employees.
There are three types of risk for medical staff. The 
first relates to their biology, the second to their environ-
ment and the third to the exposure. This tool evaluates 
the former to advise mitigation of the latter by stratifying 
individuals to lower, medium and higher risk. This biolog-
ical risk assessment tool does not in any way replace the 
need for universal precautions with appropriate personal 
protective equipment (PPE). It should only be used to 
inform the need for modification of allocated duties to 
roles with little or no direct contact with patients, such as 
‘advice and guidance’ services or virtual clinic provision. 
It incorporates and weights recognised risk factors. Many 
of these factors are predictable, such as age, gender and 
pre- existing respiratory disease, all of which have been 
associated with many previous viral infections such as 
H1N1 influenza.
The importance of pre- existing cardiovascular disease 
and cerebrovascular disease is a novel observation for a 
respiratory disease. This may be due to the method of 
cellular invasion of SARS- CoV-2 using the ACE2 enzyme, 
an enzyme which is responsible for physiological vascular 
health responses to hypertension and obesity. It does 
not, however, explain the risk associated with diabetes,27 
nor does it account for the increased risk in some ethnic 
groups.
A recent finding showed that BAME individuals account 
for 63%, 64% and 95% of deaths in the Nurse, Health-
care Assistant and Doctor staff groups, respectively.1 
These figures are substantially higher than the propor-
tional increase in BAME patients in UK ICUs (mortality 
of 18% compared with 12% in the general population).19 
Interestingly, our tool distinguished between people of 
black African descent and people of other non- European 
backgrounds, awarding a higher risk to those of West 
African descent. When validating the ORS tool against 
the OpenSafely report, however, the differential point 
award demonstrated similar overall predictive role in 
people of black African descent as other ethnicities. This 
is likely due to the different confounding disease profile 
in these populations. People of Indian subcontinent heri-
tage develop additional risk factors such as diabetes and 
premature cardiovascular disease approximately 10 years 
earlier than the European counterparts. People of black 
African descent, however, are more likely to be affected 
by unmeasured risk factors such as haemoglobinopathies 
and systemic microvascular dysfunction.28 29
Application of the ORS tool
The primary role of any risk stratification tool is to provide 
a standardised approach to individual risk management 
by identifying those with the greatest adverse conse-
quences from hazards.
Once individual risk is stratified, decisions regarding 
mitigating actions are required. Unfortunately, there 
remains uncertainty regarding the best action. The 
impact of recurrent exposure compared with high- risk 
exposures with high viral load or the environment of the 
clinical domain is uncertain. Similarly, the relative impact 
of different environments has not adequately been 
assessed. Currently, employees in front- line emergency 
and acute medical settings such as Emergency medicine, 
anaesthesia, respiratory medicine or gastroenterology 
may be considered at increased risk, as may be those who 
may need very close proximity with the patient such as 
Otorhinolaryngology (Ear Nose and Throat surgery, 
ENT) and ophthalmology. Some paradoxes have been 
observed. One recent paper found that the rate of infec-
tion with COVID-19 in staff in patient facing occupations 
was no different from that in clerical/administrative staff 
without patient contact,30 suggesting that PPE provides 
effective protection. Conversely, those later in the disease 

































  Total 227 74 16 317
Number of healthcare workers scoring low, medium and high 
risk in a validation exercise of the two tools using data from 317 
individuals working in the healthcare system.
Cohen’s kappa for agreement is 0.76; p<0.0001.
ORS, objective risk stratification; PPV, positive predictive value.
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process with severe illness (particularly at the time of 
cytokine storm requiring high dependency care) may 
have reduced viral load and shedding,31 therefore para-
doxically having a lower potential to transmit infection 
compared with those at an early stage of the disease with 
no or relatively mild symptoms.
The ORS tool enables employers to decide when to 
exclude workers from working in presumed higher risk 
environments—even if workers do not wish to do so—or 
modify the nature of their duties to fulfil the employers’ 
legal duty of care obligations to their workforce. It must be 
acknowledged that this tool is based purely on the biolog-
ical risk of an individual. The prevalence of the disease in 
the community is another determinant which should be 
considered; when prevalence is low, the increased relative 
risk may not reflect a significant absolute risk, allowing 
healthcare practitioners to return to their usual role.
Study limitations
Selection bias in testing, care and reporting can lead 
to differences in prevalence estimates of pre- existing 
risk factors and presentation across the reports from 
various countries. The majority of the existing analyses 
are based on retrospective and often single- centre series. 
No published or completed prospective cohort studies or 
randomised controlled trials were present in this litera-
ture search. A limitation is that we only searched PubMed, 
EMBASE and preprint servers. There is an urgent need 
for high- quality research using individual- level data for 
healthcare workers that will allow full mediation analyses 
to determine whether (for example) it is the age, the 
diabetes, or the cardiovascular disease that actually carries 
the greatest prognostic risk, given that these conditions 
commonly coexist, and explore the disparity in BAME 
individuals between the deaths in general population 
and the healthcare workers . There are currently only 
limited observational data on COVID-19- related deaths in 
healthcare workers or doctors, again without full access 
to all potentially pertinent information. Since this tool 
was developed, there has been significant improvement 
in the epidemiological recording of the demographics of 
those who suffer from adverse consequences of COVID-
19. The lead author has access to one of the key primary 
care record databases and uses these data for the regular 
observation and evaluation of the tool, which is currently 
on its fifth iteration. Importantly, this tool was, and 
continues to be, derived from and validated on UK data, 
and therefore may not be relevant in other countries; 
however, the methods employed here can be replicated 
in other healthcare settings.
Patient and public involvement
The primary target of this research was healthcare 
professionals, occupational health teams and medical 
managers. There was significant engagement with 
members of the British Medical Association—the trade 
union representing UK doctors—COVID-19 group and 
the staff members. Several members of this group are 
listed as coauthors, including the chair of the representa-
tive body. It is important to distinguish that these individ-
uals are reporting personal views based on their branch 
of practice, and these are not necessarily the views of the 
Association.
Concluding remarks and key messages
As part of an employer’s legal obligation under the 
Health and Safety legislation, all individuals are required 
to have a formal risk assessment. Although many organ-
isations have advocated the need for individualised risk 
evaluation, there remains no standardised methodology 
for this assessment. Without a consistent approach to 
stratification, comparing individuals’ personal risk within 
a department is difficult if not impossible. We have 
presented a robust scoring tool that allows comparisons 
and thus decisions to be made regarding the appropriate 
allocation of duties within a team. This also facilitates 
open discussion between staff who are being asked to 
work in patient facing areas and their team leaders so that 
they also understand their risks. All healthcare workers 
should wear appropriate PPE for any clinical examination 
or investigation on the basis that 20%–40% of infected 
patients, especially if less than 40 years of age, may be 
asymptomatic.32 Within a specialty team, the highest risk 
individuals should be excluded from patient facing clin-
ical areas; those at intermediate risk should have careful 
consideration to exclude them from front- line areas or 
given limited duties avoiding close contact such as in 
ENT, ophthalmology and dentistry. Those at the lowest 
risk may be assigned duties with more patient contact. 
Neither the ORS tool nor any other risk score negates the 
need for good PPE and training.
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